Advertisement

Annals of Surgical Oncology

, Volume 19, Issue 12, pp 3745–3752 | Cite as

Postoperative Bleeding Complications after Gastric Cancer Surgery in Patients Receiving Anticoagulation and/or Antiplatelet Agents

  • Kazuhito MitaEmail author
  • Hideto Ito
  • Ryo Murabayashi
  • Kouichirou Sueyoshi
  • Hideki Asakawa
  • Masashi Nabetani
  • Akira Kamasako
  • Kazuya Koizumi
  • Takashi Hayashi
Gastrointestinal Oncology

Abstract

Background

Perioperative antithrombotic treatment for gastric cancer patients receiving chronic anticoagulation and/or antiplatelet agents requires an understanding of potential bleeding and thromboembolic risks. However, no study has examined the safety aspects of perioperative antithrombotic treatment during radical gastrectomy. This study sought to evaluate postoperative bleeding and thromboembolic complications after radical gastrectomy in patients undergoing perioperative antithrombotic treatment.

Methods

The medical records of patient treated by radical gastrectomy from January 2006 to December 2010 were retrospectively reviewed. Those in the thromboprophylaxis group had received one of three regimens of perioperative antithrombotic treatment according to the clinical indications of chronic anticoagulation and/or antiplatelet agents and several published evidence-based recommendations: (1) bridging therapy with unfractionated heparin; (2) continuation of aspirin; or (3) both 1 and 2. multivariate analysis was used to identify risk factors for postoperative bleeding complications after radical gastrectomy.

Results

During the study period, 340 patients underwent radical gastrectomy. Of these, 62 patients received perioperative antithrombotic treatment; this thromboprophylaxis group had a significantly higher postoperative bleeding rate (8.1 vs. 0.7 %, P = 0.003). However, other complications, including thromboembolic events, were similar in the two study groups. Multivariate analysis revealed that perioperative antithrombotic treatment was the only independent risk factor of postoperative bleeding complications after radical gastrectomy (odds ratio, 8.53; 95 % confidence interval, 1.47–49.39; P = 0.017).

Conclusions

Perioperative antithrombotic treatment is an independent risk factor of postoperative bleeding complications in patients with gastric cancer undergoing radical gastrectomy, although such treatment was effective in preventing postoperative thromboembolic events.

Keywords

Percutaneous Coronary Intervention Antiplatelet Therapy Bleeding Complication Postoperative Bleeding Antiplatelet Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

No disclosure of any commercial, financial, or material support.

References

  1. 1.
    Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy: Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22:2767–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Degiuli M, Sasako M, Ponti A, et al. Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg. 2010;97:643–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Park DJ, Lee HJ, Kim HH, et al. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92:1099–102.PubMedCrossRefGoogle Scholar
  4. 4.
    Kim MC, Kim W, Kim HH, et al. Risk factors associated with complication following laparoscopy-assisted gastrectomy for gastric cancer: a large-scale Korean multicenter study. Ann Surg Oncol. 2008;15:2692–700.PubMedCrossRefGoogle Scholar
  5. 5.
    Jeong O, Park YK, Ryu SY, et al. Predisposing factors and management of postoperative bleeding after radical gastrectomy for gastric carcinoma. Surg Today. 2011;41:363–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents. Br J Surg. 2008;95:1437–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edn. Gastric Cancer. 1998;1:10-24.PubMedCrossRefGoogle Scholar
  8. 8.
    Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007;5:2211–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Ansell JE. The perioperative management of warfarin therapy. Arch Intern Med. 2003;163:881–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Chassot PG, Delabays A, Spahn DR. Perioperative use of anti-platelet drugs. Best Pract Res Clin Anaesthesiol. 2007;21:241–56.PubMedCrossRefGoogle Scholar
  12. 12.
    Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26:804–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation. 2007;116:e418–99.PubMedCrossRefGoogle Scholar
  14. 14.
    Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Varkarakis IM, Rais-Bahrami S, Allaf ME, et al. Laparoscopic renal-adrenal surgery in patients on oral anticoagulant therapy. J Urol. 2005;174:1020–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Ercan M, Bostanci EB, Ozer I. Postoperative hemorrhagic complications after elective laparoscopic cholecystectomy in patients receiving long-term anticoagulant therapy. Langenbecks Arch Surg. 2010;395:247–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Iqbal CW, Cima RR, Pemberton JH. Bleeding and thromboembolic outcomes for patients on oral anticoagulation undergoing elective colon and rectal abdominal operations. J Gastrointest Surg. 2011;15:2016–22.PubMedCrossRefGoogle Scholar
  18. 18.
    Mourelo R, Kaidar-Person O, Fajnwaks P, et al. Hemorrhagic and thromboembolic complications after bariatric surgery in patients receiving chronic anticoagulation therapy. Obes Surg. 2008;18:167–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Jeong O, Ryu SY, Park YK, The effect of low molecular weight heparin thromboprophylaxis on bleeding complications after gastric cancer surgery. Ann Surg Oncol. 2010;17:2363–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005;257:399–414.PubMedCrossRefGoogle Scholar
  21. 21.
    Eikelboom JW, Hirsch J. Bleeding and management of bleeding. Eur Heart J. 2006;8:G38–45.CrossRefGoogle Scholar
  22. 22.
    Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35:1288–94.PubMedCrossRefGoogle Scholar
  23. 23.
    Schouten O, van Domburg RT, Bax JJ, et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J Am Coll Cardiol. 2007;49:122–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Gershlick AH, Richardson G. Drug eluting stents. BMJ. 2006;333:1233–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45:456–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S–400S.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Kazuhito Mita
    • 1
    Email author
  • Hideto Ito
    • 1
  • Ryo Murabayashi
    • 1
  • Kouichirou Sueyoshi
    • 1
  • Hideki Asakawa
    • 1
  • Masashi Nabetani
    • 1
  • Akira Kamasako
    • 1
  • Kazuya Koizumi
    • 1
  • Takashi Hayashi
    • 1
  1. 1.Department of SurgeryNew-Tokyo HospitalMatudoJapan

Personalised recommendations